Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares of Class A common stock and restricted stock units (RSUs) for 7,500 shares of Class A common stock to three new employees under Vera's 2024 Inducement Plan (the Inducement Plan). Vera also announced that on May 6, 2024, the Compensation Committee granted additional inducement awards consisting of a non-qualified stock option to purchase 1,050 shares of Class A common stock and restricted stock units (RSUs) for 525 shares of Class A common stock to one new employee under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4).
加利福尼亚州布里斯班，2024 年 5 月 7 日（GLOBE NEWSWIRE）—— Vera Therapeutics, Inc.（纳斯达克股票代码：VERA）今天宣布，根据 Vera 的 2024 年激励计划，Vera 董事会薪酬委员会向三名新员工发放了由非合格股票期权组成的激励性奖励，用于以 7,500 股 A 类普通股购买 15,000 股 A 类普通股和限制性股票单位 (RSU) (激励计划).维拉还宣布，2024年5月6日，薪酬委员会根据激励计划向一名新员工发放了额外的激励性奖励，包括以525股A类普通股购买1,050股A类普通股和限制性股票单位（RSU）的合格股票期权。根据纳斯达克上市规则5635（c）（4），薪酬委员会批准将这些奖励作为新员工就业的激励材料。
Each stock option granted on May 1, 2024 has an exercise price per share equal to $42.32 per share, Vera's closing trading price on May 1, 2024. the stock option granted on May 7, 2024 has an exercise price per share equal to $45.00 per share, Vera's closing trading price on May 7, 2024. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. Each of the RSUs will vest over four years, with 25% of the underlying shares vesting on each anniversary of May 20, 2024, subject to the new employee's continued service relationship with Vera through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.
2024年5月1日授予的每股股票期权的行使价等于每股42.32美元，即维拉在2024年5月1日的收盘交易价格。2024年5月7日授予的股票期权的每股行使价等于每股45.00美元，即维拉在2024年5月7日的收盘交易价格。每个股票期权将在四年内归属，25％的标的股票在适用的归属开始日期一周年之际归属，标的股份的余额将在36个月内按月归属，视新员工在适用的归属日期之前与Vera的持续服务关系而定。每个限制性股票单位将在四年内归属，25％的标的股份将在2024年5月20日的每个周年纪念日归属，但要视新员工在适用的归属日期之前与Vera的持续服务关系而定。奖励受激励计划的条款和条件以及涵盖补助金的适用奖励协议的条款和条件的约束。
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera's mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger's disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit .
关于维拉
Vera Therapeutics是一家处于临床后期阶段的生物技术公司，专注于开发严重免疫疾病的治疗方法。Vera的使命是推进针对免疫疾病来源的治疗方法，以改变患者的护理标准。Vera的主要候选产品是atacicept，这是一种融合蛋白，每周一次皮下注射自行给药，可阻断B细胞活化因子（BAFF）和促增殖配体（APRIL），刺激B细胞和浆细胞产生导致某些自身免疫性疾病的自身抗体，包括IgAN（也称为伯杰氏病）和狼疮肾炎。此外，Vera正在评估其他疾病，在这些疾病中，通过阿他西普减少自身抗体可能被证明具有医学用途。Vera 还在开发 MAU868，这是一种旨在中和 BK 病毒 (BKV) 感染的单克隆抗体。BKV 是一种多瘤病毒，可能在某些环境（例如肾脏移植）中造成毁灭性后果。Vera 保留 atacept 和 MAU868 的所有全球开发和商业权利。欲了解更多信息，请访问。
For more information, please contact:
欲了解更多信息，请联系：
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
投资者联系人：
乔伊斯·阿莱尔
生命科学顾问
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Mari Purpura
LifeSci Advisors
mpurpura@lifesciadvisors.com
媒体联系人：
Mari Purpura
生命科学顾问
mpurpura@lifesciadvisors.com
译文内容由第三方软件翻译。